You just read:

Merck Receives Approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the Treatment of Chronic Hepatitis C for Patients with Genotype 1, 3, or 4 Infection Following Priority Review

News provided by

Merck Canada Inc.

Feb 03, 2016, 08:00 ET